Organization | Chengde Medical University

Chengde Medical University Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial

2018

NCT03733002

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Affiliated Hospital of Chengde Medical College | Affiliated Hospital of Chengde Medical University | Chengde Medical University

Active Ingredients

Drugs in Phase 4 Trials (4)

bacillus cereus (1 trial)

bifidobacterium animalis (1 trial)

enterococcus faecium (1 trial)

Lactobacillus acidophilus (1 trial)

Drugs in Phase 3 Trials (6)

angongniuhuang (1 trial)

capecitabine (xeloda) (1 trial)

docetaxel (taxotere) (1 trial)

paclitaxel (taxol) (1 trial)

rc48-adc (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Other Trials (1)

xingnaojing (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Cerebral Infarction (Phase 3)

Ischemia (Phase 3)

Stroke (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial APIs: 11